• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 20, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Innovative treatment restores sight in patient

Bioengineer by Bioengineer
April 30, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Innovative treatment has improved the vision of a patient suffering from a rare cancer-related syndrome affecting the eye, new research in the journal JAMA Ophthalmology reports.

In the first study of its kind, a team of researchers from the University of Surrey and Royal Surrey County Hospital, supported by the electrophysiology department of Moorfields Eye Hospital, investigated a new approach in treating melanoma-associated retinopathy (MAR), a rare auto-immune syndrome occurring in patients with cancer, which can cause night blindness and progressive vision loss.

Researchers, working with a 73 year old patient suffering with MAR, investigated if long acting steroid implants injected into the eye could improve vision and reduce symptoms. The implants slowly release fluocinolone acetonide, a corticosteroid, into the eye which prevent anti-retinal antibodies attacking proteins in the organ. Current therapies to treat patients with MAR are limited in their effectiveness and may be harmful to some.

After one week of treatment improvements in the vision of the patient were detected and detailed examination of the patient’s eye revealed that abnormalities previously observed such as reduced electroretinogram recordings had partly resolved, which is consistent with improved inner retinal cell function. Monitoring the patient over a three year period, researchers found that vision remained stable with visual acuity remaining at 20/20.

Simon Taylor, Professor of Ophthalmology at the University of Surrey and Consultant Ophthalmic Surgeon at the Royal Surrey County Hospital, said: “To our knowledge, this is the first time the vision of a patient with melanoma-associated retinopathy has been treated and significantly improved with long acting steroid implants. This offers a possible alternative treatment option to patients, whose quality of live is significantly reduced due to the symptoms of this debilitating ailment.”

The patient who underwent this pioneering treatment, said: “Every day I am extremely grateful to have had this treatment. After being diagnosed with serious melanoma, and during treatment, I developed problems with my eyes:
deterioration of my sight, discomfort and extreme disturbance. Prior to this I had enjoyed perfect sight.

“I am so thankful to Professor Taylor and the team at the Royal Surrey County Hospital for all the care I have received and restoring my eyesight.”

###

Media Contact
Natasha Meredith
n.meredith@surrey.ac.uk
http://dx.doi.org/10.1001/jamaophthalmol.2019.0284

Tags: cancerClinical TrialsHealth ProfessionalsMedicine/HealthOphthalmology
Share13Tweet8Share2ShareShareShare2

Related Posts

Jail Opioid Treatment Linkage Rates Dropped Sharply After Federal Support Ended

Jail Opioid Treatment Linkage Rates Dropped Sharply After Federal Support Ended

November 20, 2026
Auriculotherapy Shows Uncertain Hypotensive Benefit in Pilot Sinus Surgery Trial

Auriculotherapy Shows Uncertain Hypotensive Benefit in Pilot Sinus Surgery Trial

November 20, 2026

Stacking Framework Integrates Clinical and Omics Data for Accurate Survival Prediction

November 20, 2026

Dementia Training Enhances Perceived Confidence Among Primary Care Doctors in Hong Kong

November 20, 2026
Please login to join discussion

POPULAR NEWS

  • Targeting Folate Receptor Overcomes Immunotherapy Resistance in Colorectal Cancer in Mice

    Targeting Folate Receptor Overcomes Immunotherapy Resistance in Colorectal Cancer in Mice

    29 shares
    Share 12 Tweet 7
  • Jiangxi Cities Narrowed Gaps in Healthcare Workforce and Beds Over Ten Years

    29 shares
    Share 12 Tweet 7
  • Dimethoate Metabolites Pose Greater Predicted Toxicological Risks Than Parent Insecticide

    29 shares
    Share 12 Tweet 7
  • Dual-Frequency Electroacupuncture Modulates Neurotransmitters and Relieves Insomnia in Mice

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Autumn Sowing of Spring Oats Boosts Grain Yields Across European Trials

Jail Opioid Treatment Linkage Rates Dropped Sharply After Federal Support Ended

Auriculotherapy Shows Uncertain Hypotensive Benefit in Pilot Sinus Surgery Trial

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.